Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ATBPF NASDAQ:ELYM NASDAQ:NBRV OTCMKTS:RZLTD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATBPFAntibe Therapeutics$0.22$0.22$0.11▼$0.89$11.42M0.5127,352 shsN/AELYMEliem Therapeutics$1.46+4.3%$1.26$2.35▼$11.55$43.44M-0.39486,688 shs238,236 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs45 shsRZLTDRezolute$5.54+3.6%$4.27$16.00▼$24.05$46.64M4.634,788 shs920,376 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATBPFAntibe Therapeutics0.00%0.00%0.00%0.00%-0.19%ELYMEliem Therapeutics+2.19%+3.70%+10.24%+11.11%-79.56%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%RZLTDRezolute+4.70%+7.65%+22.99%+116.60%+11.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATBPFAntibe TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARZLTDRezoluteN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATBPFAntibe Therapeutics 0.00N/AN/AN/AELYMEliem Therapeutics 0.00N/AN/AN/ANBRVNabriva Therapeutics 0.00N/AN/AN/ARZLTDRezolute 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATBPFAntibe TherapeuticsN/AN/AN/AN/A$0.58 per shareN/AELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/ANBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00RZLTDRezoluteN/AN/AN/AN/A$1.24 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATBPFAntibe Therapeutics-$14.73M-$0.25N/A∞N/AN/A-56.48%-29.07%N/AELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/ANBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ARZLTDRezolute-$20.33MN/A0.00∞N/AN/A-153.46%-111.71%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATBPFAntibe TherapeuticsN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ARZLTDRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATBPFAntibe TherapeuticsN/A10.0610.06ELYMEliem TherapeuticsN/A60.4160.41NBRVNabriva Therapeutics0.120.850.52RZLTDRezoluteN/A3.263.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATBPFAntibe TherapeuticsN/AELYMEliem Therapeutics69.76%NBRVNabriva Therapeutics0.27%RZLTDRezoluteN/AInsider OwnershipCompanyInsider OwnershipATBPFAntibe Therapeutics9.00%ELYMEliem Therapeutics4.70%NBRVNabriva Therapeutics1.63%RZLTDRezolute4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATBPFAntibe Therapeutics1152.98 million48.24 millionNot OptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableRZLTDRezolute238.42 millionN/ANot OptionableATBPF, NBRV, RZLTD, and ELYM HeadlinesRecent News About These CompaniesAmerica/Resolute Time zone • Current Time in ResoluteNovember 11, 2023 | prokerala.comPRezolute (RZLT) Earnings Dates & ReportsNovember 9, 2023 | investing.comXilio Development Inc (XLO)September 3, 2023 | investing.comSystems Ltd.August 9, 2023 | forbes.comStonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye DiseaseJune 1, 2023 | benzinga.comAnalysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Jazz Pharmaceuticals (JAZZ)May 15, 2023 | markets.businessinsider.comRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company ProgressMay 12, 2023 | finanznachrichten.deRezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company ProgressMay 11, 2023 | finance.yahoo.comGreat news for Rezolute, Inc. (NASDAQ:RZLT): Insiders acquired stock in large numbers last yearApril 25, 2023 | finance.yahoo.comRezolute (RZLT) Gets a Buy from H.C. WainwrightMarch 28, 2023 | markets.businessinsider.comRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company ProgressFebruary 12, 2023 | finanznachrichten.deRezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company ProgressFebruary 10, 2023 | finance.yahoo.comXeris Biopharma Holdings Stock (NASDAQ:XERS), Quotes and News SummaryFebruary 7, 2023 | benzinga.comAfter losing 37% in the past year, Rezolute, Inc. (NASDAQ:RZLT) institutional owners must be relieved by the recent gainFebruary 2, 2023 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and Rezolute (RZLT)November 10, 2022 | markets.businessinsider.comRezolute to Present at the Jefferies London Healthcare ConferenceNovember 1, 2022 | technews.tmcnet.comNew MarketBeat Followers Over TimeATBPF, NBRV, RZLTD, and ELYM Company DescriptionsAntibe Therapeutics OTCMKTS:ATBPF$0.22 0.00 (0.00%) As of 04/16/2025Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Eliem Therapeutics NASDAQ:ELYM$1.46 +0.06 (+4.29%) As of 07/17/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Rezolute OTCMKTS:RZLTD$5.54 +0.19 (+3.55%) As of 07/17/2025Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
